Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Gintuit

Cell therapy · Cell replacement · developed by Organogenesis

Approved FDA, Mar 2012

ORGO Developer

1 Registered trials

What is Gintuit?

Gintuit is an allogeneic cell therapy composed of cultured keratinocytes and fibroblasts in bovine collagen. It is used for alveolar ridge augmentation in edentulous patients.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Mechanism: Cell replacement
Therapy area: Musculoskeletal
Developer: Organogenesis, Inc. (ORGO)
FDA status: Approved (March 9, 2012), BLA125400

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01929954	Phase 1/2	Edentulous Alveolar Ridge	Terminated	ORGO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Edentulous Alveolar Ridge

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ORGO page.

Follow ORGO, the company behind Gintuit

See ORGO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ORGO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z